CLNN
What one share of Clene holds
Pharmaceutical Preparations
We are a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (“CSN®”) therapeutics. CSN® therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form.
Clene’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$3.50 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.41 |
| Cash and investments | $0.76 |
| Debt | $1.47 |
| Book value | −$1.94 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$18.61 | $0.34 | −$15.54 | — | −$78.09 |
| 2020 | $0.24 | −$22.03 | $0.44 | −$22.07 | — | — |
| 2021 | $0.23 | −$3.16 | $0.43 | −$11.68 | — | $4.04 |
| 2022 | $0.15 | −$9.18 | $1.59 | −$13.55 | — | $0.87 |
| 2023 | $0.12 | −$9.43 | $0.06 | −$5.81 | — | $2.09 |
| 2024 | $0.05 | −$5.67 | $0.00 | −$3.07 | — | −$1.09 |
| 2025 | $0.02 | −$2.65 | $0.00 | −$1.89 | — | −$1.62 |